Jimmy Rosen is CEO of READDI, Inc., a non-profit biotechnology company created to discover and develop small molecule antiviral drugs.Prior to READDI, he was CEO of Artizan Biosciences, Inc., focused on therapies for microbiome-driven inflammatory diseases. Jimmy spent twelve years in venture capital, including leading the VC investment function for the Bill & Melinda Gates Foundation. From 2005-2015, Jimmy was a Partner at Intersouth, prior to which he spent 15 years in clinical, research, and financial positions in health care and biotech. Jimmy’s research experience includes programs at the Lineberger Comprehensive Cancer Center, the National Cancer Institute, Duke University and its Comprehensive Cancer Center. He also managed clinical trials that led to FDA-approved products. Jimmy spent several years in equity research, covering biopharmaceuticals, genomics, generics, drug delivery and medical device companies. Prior to Wall Street, he spent five years in EMS as a mountain search & rescue and ambulance medic. Jimmy holds a B.A. from Duke University, M.B.A. from UNC-Chapel Hill’s Kenan-Flagler School of Business, and M.S.P.H. from the UNC School of Public Health. He is a 2010 Eisenhower Fellow. Jimmy has served on numerous boards and advisory committees, including Chairman of the UNC Public Health Foundation (Emeritus) and Dean’s Advisory Council for the Gillings School. He is an Adjunct Assistant Professor in Health Policy & Management at the Gillings School and an Adjunct Professor at Kenan-Flagler Business School where he teaches Venture Capital finance.
